(Q33251729)

24 July 2017

6 references

13 March 2019

17 September 2019

7 November 2019

19 November 2019

16 October 2020

27 January 2021

0 references

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons (English)

1 reference

major depressive disorder

24 July 2017

main subject

6 references

13 March 2019

17 September 2019

7 November 2019

19 November 2019

16 October 2020

27 January 2021

heterocyclic compound

1 reference

17 September 2019

1 reference

7 November 2019

1 reference

7 November 2019

1 reference

7 November 2019

1 reference

19 November 2019

1 reference

second-generation antidepressive agents

1 reference

16 October 2020

1 reference

2

Christophe Lançon

1 reference

24 July 2017

Laurent Eckert

1

1 reference

24 July 2017

language of work or name

1 reference

24 July 2006

7 references

24 July 2017

13 March 2019

17 September 2019

7 November 2019

19 November 2019

16 October 2020

27 January 2021

7 references

24 July 2017

13 March 2019

17 September 2019

7 November 2019

19 November 2019

16 October 2020

27 January 2021

6

1 reference

24 July 2017

page(s)

30

1 reference

Creative Commons Attribution 2.0 Generic

24 July 2017

copyright license

6 references

13 March 2019

17 September 2019

7 November 2019

19 November 2019

16 October 2020

on focus list of Wikimedia project

27 January 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Indirect comparisons of competing interventions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Advanced methods in meta-analysis: multivariate approach and meta-regression.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Duloxetine Eli Lilly & Co.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Bias in meta-analysis detected by a simple, graphical test

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

LY248686, a new inhibitor of serotonin and norepinephrine uptake

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Venlafaxine in depressed outpatients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

The generalization of the odds ratio, risk ratio and risk difference to r x k tables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

A comparison of venlafaxine, trazodone, and placebo in major depression.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

A meta-analysis of fluoxetine outcome in the treatment of depression.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Fluoxetine-induced reduction of body mass in patients with major depressive disorder.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1552056

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-30

Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression

21 January 2018

1 reference

12 December 2020

A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression

1 reference

12 December 2020

Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group

1 reference

12 December 2020

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression

1 reference

12 December 2020

Fluoxetine response: endpoint vs pattern analysis.

1 reference

12 December 2020

Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change

1 reference

12 December 2020

Fixed-dose fluoxetine therapy for depression

1 reference

12 December 2020

A fixed-dose clinical trial of fluoxetine in outpatients with major depression

1 reference

12 December 2020

Low-dose fluoxetine therapy for depression

1 reference

12 December 2020

Placebo-controlled trial of venlafaxine for the treatment of major depression

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-244X-6-30

1 reference

Dimensions Publication ID

24 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-244x-6-30

9 September 2019

1 reference

24 July 2017

1 reference